News | March 12, 2022
Terran Biosciences acquires Concert’s CNS therapeutics portfolio
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Over the last 35 years, Dr. Moopen – Founder Chairman and Managing Director of Aster DM Healthcare has played a phenomenal role in strengthening the healthcare delivery system in GCC
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Subscribe To Our Newsletter & Stay Updated
